Preventive PCI for Vulnerable Plaques 03/07/26
Welcome to Cardiology Today â Recorded March 07, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction model and aficamten. Key takeaway: Preventive PCI for Vulnerable Plaques.
Article Links:
Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. (European heart journal)
Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. (European heart journal)
Article 3: Laminopathies: natural history and risk prediction of heart failure. (European heart journal)
Article 4: Senescence-related myocardial dysfunction: keeping a young heart. (European heart journal)
Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/preventive-pci-for-vulnerable-plaques-03-07-26/
đ Featured Articles
Article 1: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790457
Summary: Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.
Article 2: Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790132
Summary: Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.
Article 3: Laminopathies: natural history and risk prediction of heart failure.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790128
Summary: This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.
Article 4: Senescence-related myocardial dysfunction: keeping a young heart.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41790041
Summary: The myocardium undergoes significant changes with aging, impacting the heart’s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.
Article 5: Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41780565
Summary: The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population.
đ Transcript
Today’s date is March 07, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities. Advances in clinical research revealed beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes. These findings demonstrate complex interactions between metabolism and cardiac pathology. Understanding the molecular and cellular mechanisms of these agents identifies new therapeutic opportunities for cardiovascular risk reduction. This suggests a paradigm shift in managing cardiovascular risk linked to metabolic disorders.
Article number two. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. Acute myocardial ischemic syndromes frequently arise from rupture or erosion of non-flow-limiting vulnerable plaques. Optimal medical therapy leaves substantial residual cardiovascular risk, prompting consideration of preventive percutaneous coronary intervention to stabilize these high-risk lesions. Contemporary intracoronary imaging techniques, including intravascular ultrasound and optical coherence tomography, effectively identify these vulnerable plaques. The clinical argument supports preventive percutaneous coronary intervention as a default treatment strategy for these lesions, aiming to reduce future major adverse cardiovascular events.
Article number three. Laminopathies: natural history and risk prediction of heart failure. This study developed a prediction model for severe heart failure events in adult-onset laminopathies, addressing the high risk faced by patients with L. M. N. A. gene variants. Researchers included 470 adults from the French L. M. N. A. nationwide registry for derivation and an independent international cohort for validation. The model provides a tool for predicting the incidence of severe heart failure events in this patient population. This advances risk stratification for laminopathy patients.
Article number four. Senescence-related myocardial dysfunction: keeping a young heart. The myocardium undergoes significant changes with aging, impacting the heart’s pumping action. These senescence-related alterations contribute to myocardial dysfunction, a process that is not yet fully understood. Identifying the mechanisms of these age-related changes is crucial for understanding pathological processes and developing targeted therapeutic strategies. These insights hold long-term implications for maintaining cardiovascular health in an aging population.
Article number five. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. The F. O. R. E. S. T. hyphen H. C. M. study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive hypertrophic cardiomyopathy. This next-in-class, oral selective cardiac myosin inhibitor ameliorates hypercontractility in patients. The open-label study enrolled 296 patients, with a mean age of 61 years, who had completed a parent aficamten study. Results from this long-term evaluation provide crucial information on the sustained clinical profile of aficamten for this patient population.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
risk prediction model, aficamten, cardiac myosin inhibitor, long-term efficacy, percutaneous coronary intervention, therapeutic innovation, myocardial dysfunction, heart failure, cardiovascular risk, hypertrophic cardiomyopathy, pharmacological therapy, cardiac pathology, obstructive H. C. M., intracoronary imaging, vulnerable plaques, dilated cardiomyopathy, metabolic disorders, acute myocardial ischemic syndromes, cardiovascular health, laminopathy, aging heart, optimal medical therapy, pathological changes, L. M. N. A. gene variants, senescence.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow